Morbid Obesity Requiring Bariatric SurgeryNCT07564986
Relationship Between Serum Resistin Levels and Reduction in Visceral Fat in Patients Undergoing Sleeve Gastrectomy Due to Morbid Obesity
An observational study of Morbid Obesity Requiring Bariatric Surgery, run by Sercan YUKSEL, MD at 1 site in Turkey (Türkiye).
Trial summary
This study aims to investigate whether a specific protein in the blood, called resistin, can help doctors predict how much dangerous internal fat a patient will lose following weight loss surgery. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Morbid Obesity Requiring Bariatric Surgery
- What is being tested?
- Laparoscopic Sleeve Gastrectomy
- Type of treatment
- Surgery or procedure
- How many people
- 80 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Apr 2025to 27 Apr 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients applying to Başakşehir Çam Sakura City Hospital General Surgery Clinic for bariatric surgery
Who may be able to join
- Patients aged 18 to 75
- International Classification of Diseases (ICD) code E66 diagnosis (obesity)
- Patients who have given consent for sleeve gastrectomy
- Patients who are suitable for general anesthesia
Who cannot join
- Patients who did not give consent to be included in the study
- Patients who are scheduled for surgery other than sleeve gastrectomy
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Basaksehir Cam and Sakura City Hospital
Istanbul, Basaksehir, 34480
About this study
This study aims to investigate whether a specific protein in the blood, called resistin, can help doctors predict how much dangerous internal fat a patient will lose following weight loss surgery. Sleeve gastrectomy is a common and effective procedure that reduces the stomach's size to help patients lose weight and improve their metabolic health. Beyond just losing weight, it is vital to reduce visceral fat-the fat stored around internal organs-which is closely linked to inflammation and conditions like Type 2 Diabetes. Resistin is a marker known to contribute to insulin resistance and is typically higher in individuals with significant abdominal fat. By measuring resistin levels before surgery, we want to determine if this protein can serve as a guide to predict a patient's internal fat loss and overall metabolic recovery. Ultimately, this research could help healthcare providers better understand the hormonal changes that occur during weight loss and identify which patients may experience the most significant health improvements after the procedure.
- Being tested
- Laparoscopic Sleeve Gastrectomy
- Keywords
- Resistin, morbid obesity, bariatric surgery, sleeve gastrectomy
- Medical subject headings
- Obesity, Morbid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Laparoscopic Sleeve GastrectomyProcedure or surgery
Laparoscopic Sleeve Gastrectomy
| Study group | Role | What they receive |
|---|---|---|
| Sleeve Gastrectomy Patients | Patients who meet inclusion criteria for the study undergoing sleeve gastrectomy Receives: Procedure: Laparoscopic Sleeve Gastrectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in body mass index at 8 months
Measured: 8 months after surgery
Secondary outcomes (2)
Change in visseral fat at 8 months
Measured: 8 months after surgery
Change in basal metabolic rate at 8 months
Measured: 8 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2026
- Study start1 Apr 2025
- Primary completion27 Apr 2026
- Study completion27 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Morbid Obesity Requiring Bariatric SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sercan YUKSEL, MD
- Sponsor type
- Other government
- Responsible party
- Sponsor-investigator, Sercan YUKSEL, MD, Başakşehir Çam & Sakura City Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07564986
- Sponsor's protocol ID
- 2024-KAEK-11
- Status last verified
- Apr 2026
- First submitted
- 27 Apr 2026
- Last updated
- 4 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Relationship Between Serum Resistin Levels and Reduction in Visceral Fat in Patients Undergoing Sleeve Gastrectomy Due to Morbid Obesity
- ClinicalTrials.gov ID
- NCT07564986
- Acronym / sponsor ID
- 2024-KAEK-11
- Keywords
- Resistin, morbid obesity, bariatric surgery, sleeve gastrectomy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Sercan YUKSEL, MDOther government
- Study start
- 1 Apr 2025 (actual)
- Primary completion
- 27 Apr 2026 (actual)
- Study completion
- 27 Apr 2026 (actual)
- First posted
- 4 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate whether a specific protein in the blood, called resistin, can help doctors predict how much dangerous internal fat a patient will lose following weight loss surgery. Sleeve gastrectomy is a common and effective procedure that reduces the stomach's size to help patients lose weight and improve their metabolic health. Beyond just losing weight, it is vital to reduce visceral fat-the fat stored around internal organs-which is closely linked to inflammation and conditions like Type 2 Diabetes. Resistin is a marker known to contribute to insulin resistance and is typically higher in individuals with significant abdominal fat. By measuring resistin levels before surgery, we want to determine if this protein can serve as a guide to predict a patient's internal fat loss and overall metabolic recovery. Ultimately, this research could help healthcare providers better understand the hormonal changes that occur during weight loss and identify which patients may experience the most significant health improvements after the procedure.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Sleeve Gastrectomy Patients | – | Procedure: Laparoscopic Sleeve GastrectomyPatients who meet inclusion criteria for the study undergoing sleeve gastrectomy |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients applying to Başakşehir Çam Sakura City Hospital General Surgery Clinic for bariatric surgery
Key inclusion criteria (4 listed)
- Patients aged 18 to 75
- International Classification of Diseases (ICD) code E66 diagnosis (obesity)
- Patients who have given consent for sleeve gastrectomy
- Patients who are suitable for general anesthesia
Key exclusion criteria (2 listed)
- Patients who did not give consent to be included in the study
- Patients who are scheduled for surgery other than sleeve gastrectomy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Laparoscopic Sleeve GastrectomyLaparoscopic Sleeve Gastrectomy | Procedure or surgery | Sleeve Gastrectomy Patients |
Primary outcome
Change in body mass index at 8 months
Time frame: 8 months after surgery
2 secondary outcomes
Change in visseral fat at 8 months
Time frame: 8 months after surgery
Change in basal metabolic rate at 8 months
Time frame: 8 months after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2026.
Related trials for Morbid Obesity Requiring Bariatric Surgery
RecruitingObservational study
Changes in Cervical Posture, Cervical Function, and Neck Pain After Sleeve Gastrectomy
Morbid Obesity Requiring Bariatric Surgery, Neck Pain Musculoskeletal
RecruitingObservational study
Early Discharge With Hospital-at-Home After Bariatric Surgery and Economic Evaluation.
Severe Obesity, Morbid Obesity Requiring Bariatric Surgery
Not yet recruiting
Investigation of the Effects of Whole Body Vibration Application on Muscle Functional Level, Physical Fitness and Respiratory Parameters After Bariatric Surgery
Obesity & Overweight, Morbid Obesity
RecruitingObservational study
Can Pre-operative Lean Mass Predict Weight Loss After Roux-en-Y Gastric Bypass?
Morbid Obesity Requiring Bariatric Surgery
RecruitingPhase 4
Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery.
Morbid Obesity Requiring Bariatric Surgery, Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Morbid Obesity Requiring Bariatric Surgery, run by Sercan YUKSEL, MD at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in body mass index at 8 months (time frame: 8 months after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.